PCVX reported Q1 2026 results after the close on May 6 — an EPS of -$2.30 against a -$1.82 consensus estimate — capping a week in which the stock already slid 5.3% to $55.64 and short interest climbed to its highest level in over a month.
Short sellers have been steadily adding exposure to Vaxcyte since late March. Short interest has risen roughly 8.6% over the past month to reach 10.8% of the free float, with the most notable step-up occurring around April 23 when positions jumped by nearly 500,000 shares in a single session. At roughly 14.2 million shares short, this is now a meaningful position size for a mid-cap clinical-stage name. The cost to borrow, however, tells a different story: at 0.39% APR, it has actually eased about 12% on the week and sits near its lowest point in two months. Availability in the lending market remains loose — utilization picked up to 8.2% this week, up from 5.2% at the start of May, but is well below the 52-week high of 10.1% touched in mid-April. The borrow market is not tight; shorts are building into a liquid pool.
Options positioning reinforces the defensive tilt. The put/call ratio runs at 2.32, fractionally above its 20-day average of 2.30 — the z-score of roughly 1.0 suggests options traders are slightly more cautious than usual, but this is not a dramatic skew. What is notable is that the PCR has been consistently elevated throughout April, sitting in a structural range that is far closer to its 52-week put-heavy extreme of 3.22 than its low of 0.20. The market has been running a baseline hedge on this name for weeks. Together with rising short interest and a stock that has lost ground every time it tried to recover, the positioning picture heading into earnings was already defensive before the Q1 miss landed.
The analyst community remains firmly bullish despite the share price drift. All eight covering analysts carry Buy ratings, with a consensus mean price target around $104 — roughly 87% above where the stock closed Tuesday. That wide gap reflects both the ambition embedded in Vaxcyte's VAX-31 Phase 3 programme and the uncertainty of clinical-stage timelines. The most recent target adjustment on record came from BTIG in late February, lifting its target to $89 after Q4 results. Goldman Sachs initiated with Neutral and a $38 target in September 2025 — the sole dissenting voice — but note that this is now over six months stale. Bulls point to a $2.67 billion cash runway, ACIP guidelines expanding pneumococcal vaccination eligibility, and the potential size of the market; bears flag the absence of revenue, the negative EPS trend, and the degree of commercial infrastructure still to be built. The Q1 EPS miss — $2.30 versus the $1.82 estimate — adds ammunition to the cautious camp heading into the call.
Institutional ownership is concentrated and active. FMR added 1.77 million shares as recently as April 30 and now holds 9.4% of the company. T. Rowe Price added 2.6 million shares through end-March for an 8.7% stake. These are large, conviction-sized additions from long-only funds that typically anchor clinical-stage biotech positions through binary events. Against that, insider activity has been uniformly one-directional: COO James Wassil and Principal Accounting Officer Elvia Cowan have sold on multiple occasions since early March, with net insider sales of roughly $2.6 million over 90 days. Significance scores on these trades are low — they appear routine rather than strategic — but the pattern is nonetheless worth noting given the price backdrop.
Among correlated peers, the week was mixed. DNLI fell 5.7% — roughly in line with PCVX's 5.3% drop. ENGN rose 13.4% and BCYC gained 4.5%, illustrating that the broad biotech sector was not uniformly under pressure. PCVX's weakness was relatively stock-specific rather than sector-driven, which makes the magnitude of the short build in April more notable in retrospect.
With the Q1 earnings miss now public and the call scheduled for the evening of May 6, the near-term narrative centres on whether management's update on VAX-31 Phase 3 progress and the cash runway outlook is enough to satisfy an analyst community already pricing in substantial long-term upside at current levels.
See the live data behind this article on ORTEX.
Open PCVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
